Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HE3235 in advanced prostate cancer
NCT00716794Phase 2Completed
- Sponsor
- Harbor Therapeutics, Inc.
- Start
- Jul 2008
- Primary completion
- Mar 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of Apoptone in prostate cancer (PCa), sponsored by Harbor Therapeutics, Inc.. Started Jul 2008; status: completed.
02
Drugs
Apoptone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00716794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00716794.